Sanofi, GSK vaccine demonstrates strong immune responses

Observer Report

Sanofi and GSK Covid-19 vaccine candidate demonstrates strong immune responses across all adult age groups in Phase 2 trial Adjuvanted recombinant Covid-19 vaccine candidate triggered strong neutralizing antibody responses in all adult age groups High immune response after a single dose in patients with prior infection shows strong booster potential Global Phase 3 study expected to start in the coming weeks Paris and London.

The Sanofi and GSK adjuvanted recombinant Covid-19 vaccine candidate achieved strong rates of neutralizing antibody responses, in line with those measured in people who have recovered from Covid-19, in all adult age groups in a Phase 2 study with 722 volunteers.
A global pivotal Phase 3 study is expected to start in the coming weeks.

The Phase 2 interim results showed 95% to 100% seroconversion following a second injection in all age groups (18 to 95 years old) and across all doses, with acceptable tolerability and with no safety concerns.